Tectonic Therapeutic, Inc. (TECX:NASDAQ) closed at $21.30 on October 15, 2026, up 1.62% on the day. The stock trades 46.1% below its 52-week high of $39.53 and 37.2% above its 52-week low of $15.52. Over the past year, it gained 20.9%. Tectonic Therapeutic, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -6.22% | -26.48% | -35.71% | -27.12% | +20.88% |
In 252 trading sessions since October 14, 2025, TECX closed higher on 117 days (46%). Its best day was March 6, 2026 (+28.80%) and its worst was August 31, 2026 (-15.95%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 3 times.
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Find more stocks like TECX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.